{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:13:22Z","timestamp":1793384002831,"version":"4.5.0"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Blood-based measurements of total tau (T-tau) are commonly used to examine neuronal injury in patients with traumatic brain injury (TBI), but current assays do not differentiate between brain-derived tau (BD-tau) and tau produced in peripheral tissues. A novel assay for BD-tau has recently been reported that selectively quantifies nonphosphorylated tau of central nervous system origin in blood samples.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To examine the association of serum BD-tau with clinical outcomes in patients with severe TBI (sTBI) and its longitudinal changes over 1 year.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This prospective cohort study was conducted at the neurointensive unit at the Sahlgrenska University Hospital, Gothenburg, Sweden, between September 1, 2006, and July 1, 2015. The study included 39 patients with sTBI followed up for up to 1 year. Statistical analysis was performed between October and November 2021.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n \n Serum BD-tau, T-tau, phosphorylated tau\n 231<\/jats:sub>\n (p-tau\n 231<\/jats:sub>\n ), and neurofilament light chain (NfL) measured on days 0, 7, and 365 after injury.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Associations of serum biomarkers with clinical outcome and longitudinal change in sTBI. Severity of sTBI was evaluated using the Glasgow Coma Scale at hospital admission, while clinical outcome was assessed with the Glasgow Outcome Scale (GOS) at 1-year follow-up. Participants were classified as having a favorable outcome (GOS score, 4-5) or unfavorable outcome (GOS score, 1-3).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among the 39 patients (median age at admission, 36 years [IQR, 22-54 years]; 26 men [66.7%]) in the study on day 0, the mean (SD) serum BD-tau level was higher among patients with unfavorable outcomes vs those with favorable outcomes (191.4 [190.8] pg\/mL vs 75.6 [60.3] pg\/mL; mean difference, 115.9 pg\/mL [95% CI, 25.7-206.1 pg\/mL]), while the other markers had smaller between-group mean differences (serum T-tau, 60.3 pg\/mL [95% CI, \u221222.0 to 142.7 pg\/mL]; serum p-tau\n 231<\/jats:sub>\n , 8.3 pg\/mL [95% CI, \u22126.4 to 23.0 pg\/mL]; serum NfL, \u22125.4 pg\/mL [95% CI, \u221299.0 to 88.3 pg\/mL]). Similar results were recorded on day 7. Longitudinally, baseline serum BD-tau concentrations showed slower decreases in the whole cohort (42.2% on day 7 [from 138.6 to 80.1 pg\/mL] and 93.0% on day 365 [from 138.6 to 9.7 pg\/mL]) compared with serum T-tau (81.5% on day 7 [from 57.3 to 10.6 pg\/mL] and 99.0% on day 365 [from 57.3 to 0.6 pg\/mL]) and p-tau\n 231<\/jats:sub>\n (92.5% on day 7 [from 20.1 to 1.5 pg\/mL] and 95.0% on day 365 [from 20.1 to 1.0 pg\/mL]). These results did not change when considering clinical outcome, where T-tau decreased twice as fast as BD-tau in both groups. Similar results were obtained for p-tau\n 231<\/jats:sub>\n . Furthermore, the biomarker levels on day 365 were lower, compared with day 7, for BD-tau but not T-tau or p-tau\n 231<\/jats:sub>\n . Serum NfL had a different trajectory to the tau biomarkers, with levels increasing by 255.9% on day 7 compared with day 0 (from 86.8 to 308.9 pg\/mL) but decreasing by 97.0% by day 365 vs day 7 (from 308.9 to 9.2 pg\/mL).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n This study suggests that serum BD-tau, T-tau, and p-tau\n 231<\/jats:sub>\n have differential associations with clinical outcome and 1-year longitudinal change in patients with sTBI. Serum BD-tau demonstrated utility as a biomarker to monitor outcomes in sTBI and can provide valuable information regarding acute neuronal damage.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.21554","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T11:02:09Z","timestamp":1688382129000},"page":"e2321554","source":"Crossref","is-referenced-by-count":44,"title":["Association of Serum Brain-Derived Tau With Clinical Outcome and Longitudinal Change in Patients With Severe Traumatic Brain Injury"],"prefix":"10.1001","volume":"6","author":[{"given":"Fernando","family":"Gonzalez-Ortiz","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Dulewicz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"},{"name":"King\u2019s College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute London, London, United Kingdom"},{"name":"NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation London, London, United Kingdom"},{"name":"Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw R.","family":"Kac","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"},{"name":"Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, United Kingdom"},{"name":"UK Dementia Research Institute at UCL, London, United Kingdom"},{"name":"Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Andersson","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Intensive Care, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Yakoub","sequence":"additional","affiliation":[{"name":"Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer\u2019s Disease, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Hanrieder","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Turton","sequence":"additional","affiliation":[{"name":"Bioventix, Surrey, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Harrison","sequence":"additional","affiliation":[{"name":"Bioventix, Surrey, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Nellg\u00e5rd","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Intensive Care, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden"},{"name":"Department of Anesthesiology, Surgery and Intensive Care; Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"issue":"12","key":"zoi230634r1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S1474-4422(17)30371-X","article-title":"Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research.","volume":"16","author":"Maas","year":"2017","journal-title":"Lancet Neurol"},{"issue":"s10","key":"zoi230634r2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1046\/j.1528-1157.44.s10.3.x","article-title":"The epidemiology of traumatic brain injury: a review.","volume":"44","author":"Bruns","year":"2003","journal-title":"Epilepsia"},{"issue":"6","key":"zoi230634r3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/01.HTR.0000341435.52004.ac","article-title":"Prevalence of long-term disability from traumatic brain injury in the civilian population of the United States, 2005.","volume":"23","author":"Zaloshnja","year":"2008","journal-title":"J Head Trauma Rehabil"},{"key":"zoi230634r4","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.2147\/NDT","article-title":"Biomarkers in traumatic brain injury (TBI): a review.","volume":"14","author":"Dadas","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"zoi230634r5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5958\/0974-0848.2020.00005.6","article-title":"Reliability of Glasgow Coma Scale in traumatic brain injury: a retrospective analysis.","volume":"42","author":"Chawla","year":"2020","journal-title":"J Indian Forensic Med"},{"issue":"1052","key":"zoi230634r6","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20150129","article-title":"Use of multisequence 3.0-T MRI to detect severe traumatic brain injury and predict the outcome.","volume":"88","author":"Yuan","year":"2015","journal-title":"Br J Radiol"},{"issue":"9","key":"zoi230634r7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jamaneurol.2017.0655","article-title":"Comparing plasma phospho tau, total tau, and phospho tau-total tau ratio as acute and chronic traumatic brain injury biomarkers.","volume":"74","author":"Rubenstein","year":"2017","journal-title":"JAMA Neurol"},{"issue":"1","key":"zoi230634r8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1089\/neu.2018.6348","article-title":"Traumatic brain injury induces tau aggregation and spreading.","volume":"37","author":"Edwards","year":"2020","journal-title":"J Neurotrauma"},{"issue":"2","key":"zoi230634r9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3233\/JAD-150859","article-title":"The presence of select tau species in human peripheral tissues and their relation to Alzheimer\u2019s disease.","volume":"51","author":"Dugger","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"zoi230634r10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.tins.2020.04.007","article-title":"Resurrecting the mysteries of big tau.","volume":"43","author":"Fischer","year":"2020","journal-title":"Trends Neurosci"},{"issue":"3","key":"zoi230634r11","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/brain\/awac407","article-title":"Brain-derived tau: a novel blood-based biomarker for Alzheimer\u2019s disease-type neurodegeneration.","volume":"146","author":"Gonzalez-Ortiz","year":"2023","journal-title":"Brain"},{"issue":"6","key":"zoi230634r12","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1212\/WNL.0000000000009983","article-title":"Neurofilament light as a biomarker in traumatic brain injury.","volume":"95","author":"Shahim","year":"2020","journal-title":"Neurology"},{"key":"zoi230634r13","doi-asserted-by":"publisher","first-page":"36791","DOI":"10.1038\/srep36791","article-title":"Serum neurofilament light protein predicts clinical outcome in traumatic brain injury.","volume":"6","author":"Shahim","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"zoi230634r14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology.","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"11","key":"zoi230634r15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease.","volume":"217","author":"Barth\u00e9lemy","year":"2020","journal-title":"J Exp Med"},{"issue":"9","key":"zoi230634r16","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/jnnp-2020-323487","article-title":"Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration.","volume":"91","author":"Benussi","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2806834\/gonzalezortiz_2023_oi_230634_1687872017.04509.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T11:02:12Z","timestamp":1688382132000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2806834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.21554","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]}}}